文献速递乳腺外科

乳房重建与未重建对乳腺癌相关淋巴水肿影响的系统评价与Meta分析

The impact of breast reconstruction compared with no reconstruction on breast cancer-related lymphedema: A systematic review and meta-analysis.
PubMed 文献 · Surgery · 2025-09-14

Meta分析显示重建组淋巴水肿风险显著低于未重建组(IRR 0.58,95%CI 0.38-0.87,P<.001),但仅纳入有基线淋巴水肿测量研究时效应减弱;自体重建与假体重建、即刻与延期、一期与二期假体重建间无显著差异。

要点

  • 乳房重建不增加乳腺癌相关淋巴水肿风险,反而可能低于单纯乳房切除。
  • 自体重建与假体重建、即刻与延期重建之间淋巴水肿风险无显著差异。
  • 多数研究缺乏基线淋巴水肿测量且随访不足4年,证据强度受限。

核心结论

  • 乳房重建不增加乳腺癌相关淋巴水肿风险,且不同重建类型的淋巴水肿风险相似。
  • 与单纯乳房切除相比,乳房重建可能降低乳腺癌相关淋巴水肿风险。

研究设计与样本

  • 系统评价与Meta分析,遵循PRISMA指南,检索PubMed、EMBASE、Cochrane Central及灰色文献。
  • 采用随机效应模型计算发病率比(IRR),并按重建时机、类型及假体分期进行亚组分析。

主要发现

  • 乳房重建组淋巴水肿风险显著低于未重建组(IRR 0.58,95%CI 0.38-0.87,P<.001)。
  • 仅纳入有基线淋巴水肿测量的研究时,上述效应减弱。
  • 自体重建与假体重建、即刻与延期重建、一期与二期假体重建之间均无显著差异。

临床怎么用

  • 在告知患者乳房重建决策时,可说明重建不增加淋巴水肿风险,并可能降低该风险。
  • 重建类型与时机对淋巴水肿风险影响不显著,选择可更多依据肿瘤学与重建条件。

局限性

  • 多数研究缺乏基线淋巴水肿测量数据。
  • 部分研究随访时间不足4年,限制结论强度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Breast cancer-related lymphedema affects 21.9% of patients. The role of breast reconstruction in lymphedema prevention remains unclear. This review aimed to assess the relative risk of breast cancer-related lymphedema after breast reconstruction compared with mastectomy and breast-conserving surgery, which has thus far been inconclusively assessed. METHODS: We conducted a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. PubMed, EMBASE, Cochrane Central, and gray literature searches identified studies reporting lymphedema outcomes after mastectomy, breast-conserving surgery, and breast reconstruction. We calculated incidence rate ratios using random-effects models. Subgroup analyses compared reconstruction timing (immediate compared with delayed), types (autologous compared with implant-based), and immediate implant stages (1-stage compared with 2-stage). RESULTS: Twenty-three studies with 15,670 patients were included in the qualitative analysis, and 14 were included in the meta-analysis. Patients with breast reconstruction had a significantly lower risk of lymphedema than those without reconstruction (incidence rate ratio, 0.58; 95% confidence interval, 0.38-0.87, P < .001). However, this effect was less pronounced when only studies with baseline lymphedema measurements were included. We found no significant differences between autologous and implant-based reconstructions, immediate and delayed reconstruction, or 1- and 2-stage implant-based reconstruction. CONCLUSION: Breast reconstruction does not increase the risk for breast cancer-related lymphedema, and the risk of lymphedema is similar across different types of breast reconstruction. Breast reconstruction may reduce the risk of breast cancer-related lymphedema compared with mastectomy alone. The lack of baseline lymphedema measurements in most studies and studies with follow-up less than 4 years limits the strength of these findings.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Laustsen-Kiel CM, Hansen L, Ørholt M, et al. The impact of breast reconstruction compared with no reconstruction on breast cancer-related lymphedema: A systematic review and meta-analysis. Surgery. 2025. PMID: 40953534. doi:10.1016/j.surg.2025.109649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。